NeuroMetrix, Inc. Announces Date for 2012 Third Quarter Financial Results Conference Call WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 15, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 third quarter financial results before the opening of the market on October 25, 2012 .
NeuroMetrix Receives Six Month Extension of Grace Period to Regain Compliance With NASDAQ Listing Requirements WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 20, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) stating that it
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 5, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes,
NeuroMetrix Receives 510(k) Clearance for SENSUS™ Pain Management Device WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 6, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced
NeuroMetrix, Inc. Announces Date for 2012 Second Quarter Financial Results Conference Call WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 18, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 second quarter financial results before the opening of the market on July 26, 2012 .
NeuroMetrix, Inc. Announces Conference Call to Discuss American Diabetes Association 72nd Scientific Sessions and Other Business Activities WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 18, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , today said it will host a conference call at 10:00
